3 results
Primary:*To identify the maximum tolerated dose (MTD) and to investigate the pharmacokinetics (PK) of a single dose of lanreotide PRF in subjects with acromegalySecondary:*To investigate the safety and tolerability of a single dose of lanreotide PRF…
To evaluate the safety and performance of the Neovasc Tiara MitralTranscatheter Heart Valve with the Tiara Transapical Delivery System.Data collected in this clinical study will include 30-day safety and performance ofthe device and delivery system…
Primary Objective* To describe the antitumour efficacy of LAN monotherapy plus BSC every 28 days, in terms of progression-free survival (PFS), measured by central review using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria,…